Niagen Bioscience, Inc. (NAGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.69 Million) by net assets ($70.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NAGE net asset quality index to measure how much of total assets are equity-financed.
Niagen Bioscience, Inc. - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Niagen Bioscience, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NAGE cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Niagen Bioscience, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Niagen Bioscience, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bombay Dyeing & Mfg Company Limited
NSE:BOMDYEING
|
-0.019x |
|
Mount Gibson Iron Ltd
AU:MGX
|
0.026x |
|
Hainan Yedao Group Co Ltd
SHG:600238
|
-0.076x |
|
Shanghai Lisheng Racing Co Ltd
SHE:002858
|
0.016x |
|
Know IT AB
ST:KNOW
|
0.027x |
|
UNID Company Ltd
KO:014830
|
-0.030x |
|
Escalade Incorporated
NASDAQ:ESCA
|
0.035x |
|
Jiangshan Oupai Door Industry Co Ltd
SHG:603208
|
0.079x |
Annual Cash Flow Conversion Efficiency for Niagen Bioscience, Inc. (2007–2024)
The table below shows the annual cash flow conversion efficiency of Niagen Bioscience, Inc. from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see Niagen Bioscience, Inc. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $46.09 Million | $12.11 Million | 0.263x | +5.04% |
| 2023-12-31 | $28.46 Million | $7.12 Million | 0.250x | +147.50% |
| 2022-12-31 | $28.67 Million | $-15.10 Million | -0.527x | +30.86% |
| 2021-12-31 | $31.73 Million | $-24.16 Million | -0.762x | -18.00% |
| 2020-12-31 | $16.42 Million | $-10.60 Million | -0.645x | +35.44% |
| 2019-12-31 | $20.45 Million | $-20.44 Million | -1.000x | -29.95% |
| 2018-12-31 | $27.18 Million | $-20.91 Million | -0.769x | -322.42% |
| 2017-12-31 | $53.83 Million | $-9.80 Million | -0.182x | +38.14% |
| 2016-12-31 | $9.97 Million | $-2.94 Million | -0.294x | +26.44% |
| 2015-12-31 | $5.27 Million | $-2.11 Million | -0.400x | +37.98% |
| 2014-12-31 | $4.00 Million | $-2.58 Million | -0.645x | +6.39% |
| 2013-12-31 | $5.67 Million | $-3.91 Million | -0.689x | +72.79% |
| 2012-12-31 | $3.99 Million | $-10.12 Million | -2.534x | -58.35% |
| 2011-12-31 | $2.56 Million | $-4.10 Million | -1.600x | -196.80% |
| 2010-12-31 | $4.94 Million | $-2.66 Million | -0.539x | -42.56% |
| 2009-12-31 | $1.05 Million | $-396.17K | -0.378x | +65.57% |
| 2008-12-31 | $1.75 Million | $-1.92 Million | -1.098x | +99.49% |
| 2007-12-31 | $180.00 | $-38.48K | -213.794x | -- |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+)… Read more